Table 3.

Multivariate analysis of CXCR3 prognostic factors in patients not treated with tamoxifen

Marker	P-value	Risk ratio
Breast cancer survival
CXCR3	0.048494	1.59 95 % CI (12.52)
CXCL10	0.807265	0.96 95 % CI (0.72–1.29)
ER 10 %	0.231437	0.65 95 % CI (0.32–1.32)
Pgr 10 %	0.498511	1.27 95 % CI (0.64–2.51)
HER2	0.224406	1.59 95 % CI (0.75–3.33)
Size <20 mm	0.000161	2.85 95 % CI (1.66–4.91)
Local recurrence-free survival
CXCR3	0.29	1.29 95 % CI (0.8–2.07)
CXCL10	0.35	1.21 95 % CI (0.81–1.79)
ER 10 %	0.31	0.59 95 % CI (0.22–1.63)
Pgr 10 %	0.1	2.13 95 % CI (0.86–5.28)
HER2	0.73	1.22 95 % CI (0.39–3.83)
Size <20 mm	0.57	0.78 95 % CI (0.34–1.81)
Distant metastasis
CXCR3	0.017	1.61 95 % CI (1.09–2.38)
CXCL10	0.49	0.91 95 % CI (0.71–1.17)
ER 10 %	0.15	0.61 95 % CI (0.32–1.18)
Pgr 10 %	0.048	1.85 95 % CI (1.01–3.42)
HER2	0.15	1.65 95 % CI (0.83–3.27)
Size <20 mm	0.00031	2.41 95 % CI (1.49–3.89)